91 related articles for article (PubMed ID: 27352825)
1. Differential expression of cancer stem cell markers in cutaneous and systemic lymphoma.
Nicolay JP; Schneider S; Gaiser T; Felcht M; Klemke CD
Exp Dermatol; 2016 Jul; 25(7):561-3. PubMed ID: 27352825
[No Abstract] [Full Text] [Related]
2. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
3. [Comparative analysis of the expression of cell adhesion molecules in cutaneous T-cell lymphomas (mycosis fungoides/Sézary syndrome) and inflammatory skin diseases].
López-Lerma I; Estrach MT
Actas Dermosifiliogr; 2010 Dec; 101(10):866-77. PubMed ID: 21159263
[TBL] [Abstract][Full Text] [Related]
4. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of lymphangiogenic markers in Sézary syndrome.
Karpova MB; Fujii K; Jenni D; Dummer R; Urosevic-Maiwald M
Leuk Lymphoma; 2011 Mar; 52(3):491-501. PubMed ID: 20846094
[TBL] [Abstract][Full Text] [Related]
6. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
Wong HK
Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
[TBL] [Abstract][Full Text] [Related]
7. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma.
Speigl L; Janssen N; Weide B; Pawelec G; Shipp C
Br J Dermatol; 2017 Nov; 177(5):1447-1449. PubMed ID: 27870003
[No Abstract] [Full Text] [Related]
11. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells.
Moins-Teisserenc H; Daubord M; Clave E; Douay C; Félix J; Marie-Cardine A; Ram-Wolff C; Maki G; Beldjord K; Homyrda L; Michel L; Bensussan A; Toubert A; Bagot M
J Invest Dermatol; 2015 Jan; 135(1):247-257. PubMed ID: 25158034
[TBL] [Abstract][Full Text] [Related]
12. Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma.
Suga H; Sugaya M; Miyagaki T; Kawaguchi M; Morimura S; Kai H; Kagami S; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Eur J Dermatol; 2013; 23(5):629-35. PubMed ID: 24001451
[TBL] [Abstract][Full Text] [Related]
13. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Maj J; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6017-26. PubMed ID: 26504025
[TBL] [Abstract][Full Text] [Related]
14. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
15. Tumor Stage Mycosis Fungoides in a Child.
Dulmage BO; Villaseñor-Park J; Ho J; Geskin LJ; Grandinetti LM
Pediatr Dermatol; 2015; 32(4):e156-8. PubMed ID: 25892093
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
17. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
[TBL] [Abstract][Full Text] [Related]
19. [An update: stem cell and cancer stem cells].
Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):511-2. PubMed ID: 20021959
[No Abstract] [Full Text] [Related]
20. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
